Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations

PaperCitations, authors & open-access status

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 84 citations, 2023 year and green oa status.

84
Citations
2023
Year
green
OA Status

Related on ScholarIQ

Yusuke Okuma
Author
JAMA Oncology
Journal
Lung Cancer Treatments and Mutations
Topic
Lung Cancer Treatments and Mutations
Topic
Lung Cancer Research Studies
Topic
Fibroblast Growth Factor Research
Topic
470M+ articles · free account